OSI Pharmaceuticals (OSIP) - formerly Oncogene Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (166)	12/25/2002 12:21:07 AM
From: fred hayes	Read Replies (1) of 447

>>Why both compound skipped PII combination trials???<< Good question, and sorry for the untimely response. Cleaning out some files tonight, too wound up from Christmas eve to go to bed yet. Looking at an OSIP press release dated may 17, 1999 re CP-358,774, which becomes Tarceva. First para last sentence, "A large scale Phase II clinical program testing the efficacy of CP-358,774 against a variety of tumors, both as a single agent and in combination with existing chemotherapy regimens, has been initiated." Really? Note that it says it has been initiated, not that they are thinking about it. But I have no notes or record of P2 results in combo therapy, and have been under the impression that no P2 combo trials with Tarceva have been done. Anybody have any recollection of P2 results with combo therapy? If not, what should we make of this statement from OSIP? Pretty clear that results from P2 combo trials would be pretty important in evaluating Tarceva's chances in light of what happened to Iressa. I don't know how to reconcile this info. Maybe I'm misreading it. Any thoughts? fred

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next